Mr. Mark Upsdell reports

RAPID DOSE THERAPEUTICS (DOSE) (RDTCF) SECURES PATENT FOR QUICKSTRIP NICOTINE ORAL FILM TARGETING $38B SMOKE-FREE NICOTINE MARKET

Rapid Dose Therapeutics Corp. has been granted a key patent for its QuickStrip nicotine bilayer oral film in partnership with Aavishkar Oral Strips.

The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under patent No. IN 582202, based on patent application No. IN 202441055689, filed July 22, 2024, under the Patent Cooperation Treaty framework.

The patent covers Rapid Dose Therapeutics' bilayer oral thin-film technology designed for controlled nicotine delivery, including proprietary formulation and manufacturing processes that support rapid absorption and discreet administration through dissolvable oral strips.

The grant represents a major step in the company's global intellectual property strategy, which began with its World Intellectual Property Organization PCT filing, announced in May, 2025. That filing extended potential patent protection to up to 158 jurisdictions worldwide, strengthening the company's global positioning within the rapidly expanding smoke-free nicotine products market.

The global modern oral nicotine market was valued at approximately $7.96-billion in 2024 and is projected to reach $38.89-billion by 2033, growing at a 19-per-cent compound annual growth rate. Growth is being driven by increasing demand for smoke-free nicotine alternatives, rising awareness of the health risks of combustible cigarettes, and continued innovation in nicotine replacement therapy and oral nicotine delivery systems.

Rapid Dose Therapeutics' QuickStrip oral thin-film platform is designed to deliver active ingredients -- including nicotine, pharmaceuticals, nutraceuticals and vaccines -- through fast-dissolving oral films that enable rapid onset and improved bioavailability.

India represents both a significant consumer market and a major global pharmaceutical manufacturing hub, making the patent strategically important as Rapid Dose continues executing its global expansion strategy. In addition, the company intends to register the patent in other jurisdictions, providing commercial opportunities in those jurisdictions by utilizing the rights granted by the jurisdictions for patent protection.

The company also noted that the milestone provides further opportunity for commercial discussions with a major global nicotine company, with which Rapid Dose has been engaged for nearly three years.

"This patent grant is clear evidence that RDT is delivering on the strategy we communicated to investors," said Jason Lewis, senior vice-president, business development, and co-inventor. "Our May, 2025, WIPO filing was the first step in establishing broad international protection. The PCT patent issuance, in partnership with Aavishkar, is a key milestone for systematically securing key jurisdictions and strengthening our global negotiating position."

Strengthening competitive position

The company believes that the combination of:

• Broad international PCT coverage extending to 158 jurisdictions;
• Granted patent protection; and
• A strategic joint ownership structure with Aavishkar positions Rapid Dose to advance commercial agreements from a position of strength while protecting shareholder value.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.